ES2507508T3 - Terapia anticancerígena enzimática - Google Patents

Terapia anticancerígena enzimática Download PDF

Info

Publication number
ES2507508T3
ES2507508T3 ES08754910.1T ES08754910T ES2507508T3 ES 2507508 T3 ES2507508 T3 ES 2507508T3 ES 08754910 T ES08754910 T ES 08754910T ES 2507508 T3 ES2507508 T3 ES 2507508T3
Authority
ES
Spain
Prior art keywords
adenosine deaminase
tumor
ada
recombinant
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08754910.1T
Other languages
English (en)
Spanish (es)
Inventor
David R. Filpula
Puja Sapra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma-Tau Rare Diseases S A
Original Assignee
Sigma-Tau Rare Diseases S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Rare Diseases S A filed Critical Sigma-Tau Rare Diseases S A
Application granted granted Critical
Publication of ES2507508T3 publication Critical patent/ES2507508T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES08754910.1T 2007-04-20 2008-04-18 Terapia anticancerígena enzimática Active ES2507508T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
US913039P 2007-04-20
PCT/US2008/060733 WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Publications (1)

Publication Number Publication Date
ES2507508T3 true ES2507508T3 (es) 2014-10-15

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08754910.1T Active ES2507508T3 (es) 2007-04-20 2008-04-18 Terapia anticancerígena enzimática

Country Status (19)

Country Link
US (1) US8741283B2 (cg-RX-API-DMAC7.html)
EP (1) EP2147122B1 (cg-RX-API-DMAC7.html)
JP (1) JP5595904B2 (cg-RX-API-DMAC7.html)
KR (1) KR101540296B1 (cg-RX-API-DMAC7.html)
CN (1) CN101680039B (cg-RX-API-DMAC7.html)
BR (1) BRPI0810384B8 (cg-RX-API-DMAC7.html)
CA (1) CA2684749C (cg-RX-API-DMAC7.html)
CY (1) CY1117000T1 (cg-RX-API-DMAC7.html)
DK (1) DK2147122T3 (cg-RX-API-DMAC7.html)
ES (1) ES2507508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140947T1 (cg-RX-API-DMAC7.html)
IL (1) IL201593A (cg-RX-API-DMAC7.html)
MX (1) MX2009011320A (cg-RX-API-DMAC7.html)
NZ (1) NZ580980A (cg-RX-API-DMAC7.html)
PL (1) PL2147122T3 (cg-RX-API-DMAC7.html)
PT (1) PT2147122E (cg-RX-API-DMAC7.html)
SI (1) SI2147122T1 (cg-RX-API-DMAC7.html)
TW (1) TWI486169B (cg-RX-API-DMAC7.html)
WO (1) WO2008131163A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005333165B2 (en) 2004-11-12 2012-07-19 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2147116B1 (en) 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
EP3178932A1 (en) * 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
EP3426299A4 (en) * 2016-03-11 2019-10-16 University of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR TREATMENT OF TUMORS
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
US20240250753A1 (en) * 2022-10-10 2024-07-25 Berkeley Marine Robotics Inc. Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
AU2001297556A1 (en) * 2000-11-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU2002365360A1 (en) * 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CA2653061A1 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
CN101534861B (zh) 2006-09-15 2013-10-02 安佐制药股份有限公司 具有基于位阻酯的生物可降解连接基的聚环氧烷
WO2008083302A2 (en) * 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
EP2147116B1 (en) 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase

Also Published As

Publication number Publication date
CN101680039B (zh) 2016-08-24
EP2147122A4 (en) 2010-11-17
WO2008131163A8 (en) 2010-01-28
RU2009142817A (ru) 2011-05-27
EP2147122B1 (en) 2014-07-16
BRPI0810384B1 (pt) 2021-02-02
CA2684749C (en) 2016-06-21
SI2147122T1 (sl) 2015-01-30
PL2147122T3 (pl) 2015-05-29
US20090047270A1 (en) 2009-02-19
BRPI0810384A2 (pt) 2014-11-04
US8741283B2 (en) 2014-06-03
CN101680039A (zh) 2010-03-24
TWI486169B (zh) 2015-06-01
CY1117000T1 (el) 2017-04-05
MX2009011320A (es) 2009-12-15
JP2010524968A (ja) 2010-07-22
KR20090130108A (ko) 2009-12-17
AU2008242791A1 (en) 2008-10-30
CA2684749A1 (en) 2008-10-30
HRP20140947T1 (hr) 2015-02-13
WO2008131163A1 (en) 2008-10-30
DK2147122T3 (da) 2014-10-13
TW200902051A (en) 2009-01-16
KR101540296B1 (ko) 2015-07-31
NZ580980A (en) 2012-04-27
PT2147122E (pt) 2014-10-15
JP5595904B2 (ja) 2014-09-24
BRPI0810384B8 (pt) 2021-05-25
IL201593A (en) 2017-07-31
IL201593A0 (en) 2010-05-31
EP2147122A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
ES2507508T3 (es) Terapia anticancerígena enzimática
Altai et al. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
KR101394768B1 (ko) 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
ES2923152T3 (es) Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos
ES2872964T3 (es) Inmunoconjugado de IL-12
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ES2909664T3 (es) Composición farmacéutica que comprende arginina desiminasa de unión a albúmina para el tratamiento dirigido del cáncer
BRPI0810383A2 (pt) adenosina deaminase recombinante estável
PL238187B1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
JP7658627B2 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
RU2481855C2 (ru) Ферментативная противоопухолевая терапия
AU2008242791B2 (en) Enzymatic anticancer therapy
KR20250164783A (ko) 펩티드의 공유 결합 변형을 위한 양이온성 지질
JP2025541902A (ja) ペプチドの水性製剤を含む医療用製品
HK1142634A (en) Enzymatic anticancer therapy
WO2024238969A1 (en) Trans-cyclooctene-modified targeted protein degrader conjugates
RU2486246C2 (ru) Стабильная рекомбинантная аденозиндеаминаза
CN118497178A (zh) 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用
CN104136038A (zh) 体腔积液抑制剂
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
CN105936643A (zh) 具有抑制癌细胞生长活性的肽及其应用